Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects
Xuemei He,1 Kazuya Narushima,2 Masahiro Kojima,2 Chisato Nagai,2 Kexin Li1 1Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Applic...
Saved in:
Main Authors: | He X (Author), Narushima K (Author), Kojima M (Author), Nagai C (Author), Li K (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans
by: Kazuya Narushima, et al.
Published: (2019) -
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
by: Masaya Tachibana, et al.
Published: (2023) -
Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
by: Shigematsu T, et al.
Published: (2018) -
Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment
by: Mirjam Kuipers, et al.
Published: (2006) -
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
by: Cheng Y, et al.
Published: (2023)